Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02718157 · ClinicalTrials.gov registry record · NA

Validation of the GenePOC GBS Assay for the Detection of the Cfb Gene From Streptococcus Agalactiae Strains

A NA study, sponsored by Meridian Bioscience.

Completed
Registry status
NA
Development phase
771
Enrollment target

NCT02718157: Completed NA study, sponsored by Meridian Bioscience.

NCT02718157 is a NA study that has completed, run by Meridian Bioscience. The registered enrollment target is 771 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (45% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02718157, a NA study, has completed, sponsored by Meridian Bioscience.

COMPLETED
Registry status
NA
Development phase
771 participants
Enrollment target

Study Summary

The primary purpose of this clinical investigation is to verify the performance of the GenePOC GBS Assay on the GenePOC Instrument. This will be achieved by comparing the Assay to the a Culture, a conventional method for detection of Streptococcus agalactiae in vaginal/rectal swab specimens from antepartum women.

Primary Outcome

To establish the performance characteristics of the GenePOC GBS System for its use in determining the presence of GBS in vaginal/rectal swab, after Lim Broth enrichment, specimens from antepartum pregnant women. Sensitivity and specificity will be established in comparison to the Reference Method. Sensitivity performance results from the comparison of specimens being reported as positive by both method against the total number of specimen reported as positive on the Reference Method only. Sensi

Interventions

  • DEVICE Comparison between GenePOC PCR and Reference Method

Trial Details

FieldValue
Enrollment Target 771 participants
Start Date 2016-08-10
Est. Completion 2017-02-07
Phase NA
Meridian Bioscience

19 total trials

What the finished NCT02718157 record still lists

NCT02718157 is an interventional study that assigns participants to a tested intervention. The registered 771 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (45% lower).

The record links to 0 conditions, and to 1 intervention - of which Comparison between GenePOC PCR and Reference Method is the first listed.

NCT02718157 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02718157 about?

NCT02718157 is a clinical study titled "Validation of the GenePOC GBS Assay for the Detection of the Cfb Gene From Streptococcus Agalactiae Strains". The primary purpose of this clinical investigation is to verify the performance of the GenePOC GBS Assay on the GenePOC Instrument. This will be achieved by comparing the Assay to the a Culture, a conventional method for detection of Streptococcus agalactiae in vaginal/rectal swab specimens from ant...

What is the current status of trial NCT02718157?

This trial is currently completed. It is a NA study. The enrollment target is 771 participants. The study started on 2016-08-10. Estimated completion is 2017-02-07.

What interventions are being tested in trial NCT02718157?

The interventions under investigation include: Comparison between GenePOC PCR and Reference Method (DEVICE).

Who is sponsoring clinical trial NCT02718157?

This trial is sponsored by Meridian Bioscience, which has 19 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02718157's enrollment target sits among peer trials

771 143rd of 2000 higher than 1,858 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05977348 · 770 participants · NA

    Increasing Food Literacy in Preschoolers to Reduce Obesity Risk

  • NCT06376994 · 770 participants · Phase 3

    Multi-Center Clean Air Randomized Controlled Trial in COPD

  • NCT06824467 · 770 participants · Phase 3

    A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

  • NCT06907173 · 770 participants · Phase 3

    Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02718157, the US trial registry maintained by the National Library of Medicine. NCT02718157 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.